EUVIMEDEUVIMED entdecken
Open Access

Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling

Jacqueline A Turner, Robert J Van Gulick, William A Robinson, Tariq Mughal, Richard P Tobin, Morgan L MacBeth, Blair Holman, Anthony Classon, Stacey M Bagby, Betelehem W Yacob, Sarah J Hartman, Ian Silverman und 15 weitere

International Journal of Cancer · 2024

DOI: 10.1002/ijc.35087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Jacqueline A Turner und 26 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Dasatinib, Mucous Membrane. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Patten-Davis Foundation, American Cancer Society, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advancements in treating cutaneous melanoma, patients with acral and mucosal (A/M) melanomas still have limited therapeutic options and poor prognoses. We analyzed 156 melanomas (101 cutaneous, 28 acral, and 27 mucosal) using the Foundation One cancer‐gene specific clinical testing platform and identified new, potentially targetable genomic alterations (GAs) in specific anatomic sites of A/M melanomas. Using novel pre‐clinical models of A/M melanoma, we demonstrate that several GAs and corresponding oncogenic pathways associated with cutaneous melanomas are similarly targetable in A/M melanomas. Other alterations, including MYC and CRKL amplifications, were unique to A/M melanomas and susceptible to indirect targeting using the BRD4 inhibitor JQ1 or Src/ABL inhibitor dasatinib, respectively. We further identified new, actionable A/M‐specific alterations, including an inactivating NF2 fusion in a mucosal melanoma responsive to dasatinib in vivo . Our study highlights new molecular differences between cutaneous and A/M melanomas, and across different anatomic sites within A/M, which may change clinical testing and treatment paradigms for these rare melanomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsDasatinibMucous MembraneHumansMaleFemaleMiddle AgedAnimalsAgedMiceCell Line, TumorAdultGenomicsTriazolesAzepinesMolecular Targeted TherapyGene Expression Profiling

Stichwörter der Autor:innen

CRKLMYCNF2acraldasatinibfusionsmelanomamucosal

Substanzen

DasatinibTriazoles(+)-JQ1 compoundAzepines

Autor:innen und Institutionen

  • Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Division of Hematology-Oncology, Tufts University Cancer Center, Boston, Massachusetts, USA.
  • Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Foundation Medicine Inc., Cambridge, Massachusetts, USA.
  • Ignyta, Inc., San Diego, California, USA.

ORCID-Profile: Kasey L Couts

Förderung

  • Patten-Davis Foundation
  • American Cancer Society
  • NCI NIH HHS
  • Moore Family Foundation
  • Paul R. Ohara II Seed Grant Program
  • National Cancer Institute

Zitieren

APA

Turner, J. A., Van Gulick, R. J., Robinson, W. A., Mughal, T., Tobin, R. P., MacBeth, M. L., Holman, B., Classon, A., Bagby, S. M., Yacob, B. W., Hartman, S. J., Silverman, I., Vorwald, V. M., Gorden, N., Gonzalez, R., Gay, L. M., Ali, S. M., Benson, A., Miller, V. A., …, & Couts, K. L. (2024). Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling. International Journal of Cancer. https://doi.org/10.1002/ijc.35087

Vancouver

Turner JA, Van Gulick RJ, Robinson WA, Mughal T, Tobin RP, MacBeth ML, et al. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling. International Journal of Cancer. 2024. doi:10.1002/ijc.35087

BibTeX
@article{Turner2024,
  author = {Turner, Jacqueline A and Van Gulick, Robert J and Robinson, William A and Mughal, Tariq and Tobin, Richard P and MacBeth, Morgan L and Holman, Blair and Classon, Anthony and Bagby, Stacey M and Yacob, Betelehem W and Hartman, Sarah J and Silverman, Ian and Vorwald, Victoria M and Gorden, Nicholas and Gonzalez, Rita and Gay, Laurie M and Ali, Siraj M and Benson, Adam and Miller, Vincent A and Ross, Jeffrey S and Pitts, Todd M and Rioth, Matthew J and Lewis, Karl D and Medina, Theresa and McCarter, Martin D and Gonzalez, Rene and Couts, Kasey L},
  title = {Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.35087}
}
Kostenlos starten →